XML 75 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Details)
3 Months Ended 9 Months Ended
Dec. 10, 2020
USD ($)
Nov. 11, 2019
USD ($)
tranche
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Nov. 25, 2019
USD ($)
Line of Credit Facility [Line Items]                
Derivative liability     $ 1,930,000   $ 1,930,000   $ 2,420,000  
Collateral Agent, Pharmakon                
Line of Credit Facility [Line Items]                
Derivative liability     1,900,000   1,900,000   $ 2,400,000  
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon                
Line of Credit Facility [Line Items]                
Line of credit, maximum borrowing capacity   $ 100,000,000            
Line of credit, maximum borrowing capacity, number of available tranches | tranche   2            
Term loan, maturity term   5 years            
Term loan, maturity term, potential reduction (up to)   1 year            
Term loan, amortization period, potential reduction (up to)   1 year            
Facility fee percentage on principal amount   2.00%            
Facility fee paid, amount   $ 2,000,000            
Prepayment premium percentage on principal if prepaid prior to third anniversary of funding   2.00%            
Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding   1.00%            
Prepayment premium percentage on principal if prepaid after fourth anniversary of funding   0.50%            
Interest expense     $ 2,700,000 $ 2,200,000 $ 8,100,000 $ 6,600,000    
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Debt Instrument, Quarterly Periodic Payment, Period One                
Line of Credit Facility [Line Items]                
Term loan, first quarterly principal payment due in   33 months            
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Debt Instrument, Quarterly Periodic Payment, Period Two                
Line of Credit Facility [Line Items]                
Term loan, first quarterly principal payment due in   48 months            
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Three-month LIBOR                
Line of Credit Facility [Line Items]                
Basis spread on floating interest rate   7.50%            
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | LIBOR                
Line of Credit Facility [Line Items]                
Debt instrument, floor rate   2.00%            
Debt instrument, cap rate   3.35%            
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche A                
Line of Credit Facility [Line Items]                
Line of credit, maximum borrowing capacity   $ 80,000,000            
Term loan, net of facility fees, lender expenses and issuance costs               $ 77,300,000
Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche B                
Line of Credit Facility [Line Items]                
Line of credit, maximum borrowing capacity   $ 20,000,000            
BPCR Limited Partnership | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche B                
Line of Credit Facility [Line Items]                
Proceeds from line of credit $ 20,000,000